These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management. Mahasandana C; Patharathienskul D; Suvatte V Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549 [TBL] [Abstract][Full Text] [Related]
4. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia. McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730 [TBL] [Abstract][Full Text] [Related]
5. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX]. Iizuka A; Kuwashima M; Nagao T Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811 [No Abstract] [Full Text] [Related]
6. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B. Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502 [TBL] [Abstract][Full Text] [Related]
8. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185 [No Abstract] [Full Text] [Related]
12. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX. Nilsson IM; Berntorp E Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694 [No Abstract] [Full Text] [Related]
13. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies. Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234 [No Abstract] [Full Text] [Related]
14. [Characteristics of the diagnosis, clinical aspects and treatment of hemophilias with specific, circulating anticoagulants]. Barkagan ZS; Sukhoveeva EIa; Eremin GF; Tolochko OI; Shevchenko VI Probl Gematol Pereliv Krovi; 1972 Apr; 17(4):35-41. PubMed ID: 4680852 [No Abstract] [Full Text] [Related]
15. [Inhibitors and "bypass" therapy in hemophilia]. Fukutake K; Fukutake K Nihon Rinsho; 1981; 39(12):3688-99. PubMed ID: 6803034 [No Abstract] [Full Text] [Related]
18. Letter: Rising factor VIII inhibitor titers after Konyne factor IX complex. Kasper CK; Feinstein DI N Engl J Med; 1976 Aug; 295(9):505-6. PubMed ID: 59902 [No Abstract] [Full Text] [Related]
19. [Determination of factor VIII inhibitor in hemophiliacs]. Mancini AF; Rosito P; Paolucci G Minerva Pediatr; 1976 Nov; 28(36):2181-5. PubMed ID: 995099 [No Abstract] [Full Text] [Related]
20. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII. Kantrowitz JL; Lee ML; McClure DA; Kingdon HS; Thomas WR Clin Ther; 1987; 9(4):405-19. PubMed ID: 3111706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]